Applied Evidence

Is platelet-rich plasma right for your patient?

Author and Disclosure Information

 

References

Platelet-rich plasma is approved only for use in the operative setting to enhance bone graft handling properties. Office-based injections are an off-label use.

We should keep in mind, too, that the evidence for many of the other treatment options for both tendinopathy and knee OA are similarly problematic, and these modalities are even more widely used than PRP. Given the systemic problems associated with nonsteroidal anti-inflammatory drugs, concerns about possible tendon rupture with corticosteroid injections, and the time and compliance issues associated with PT, PRP may be a safer alternative to more traditional treatments.

An off-label use. PRP does not pass through the standard regulatory pathway of the US Food and Drug Administration (FDA). As a blood product, PRP falls under the regulatory purview of the FDA’s Center for Biologics Evaluation and Research, which has approved PRP only for use in the operative setting to enhance bone graft handling properties.27 Therefore, office-based PRP injections are an off-label use of the treatment.

CASE 1 › You explain to Ms. T that PRP injections are not covered by insurance and that there is not a significant amount of evidence to indicate that an injection would appreciably improve her pain. She decides to proceed with a knee replacement and not to pursue a PRP injection.

CASE 2Given the time that Mr. H has invested in traditional conservative management strategies, his time away from work, and that he is not concerned with the out-of-pocket cost associated with PRP, you explain to him that there is some limited evidence that PRP might improve his symptoms. He decides that he would rather try a PRP injection than pursue surgery.

CORRESPONDENCE
Jordan White, MD, MPH, Department of Family Medicine, 111 Brewster Street, Pawtucket, RI 02860; jordan_white@brown.edu.

Pages

Recommended Reading

Drug-eluting stent recipients can safely have surgery sooner
MDedge Family Medicine
Standard incubation can miss P. acnes in infective endocarditis
MDedge Family Medicine
VIDEO: HOPE-3 bolsters primary prevention in intermediate-risk patients
MDedge Family Medicine
DANAMI 3-iPOST: No significant benefit with ischemic postconditioning after STEMI
MDedge Family Medicine
Psoriasis tied to abdominal aortic aneurysm in nationwide study
MDedge Family Medicine
Ticagrelor cuts post-MI events in diabetes patients
MDedge Family Medicine
PPI cuts GI events from low- and high-dose aspirin
MDedge Family Medicine
Earlier bariatric surgery may improve cardiovascular outcomes
MDedge Family Medicine
Who benefits most from aspirin to prevent CVD and colorectal cancer?
MDedge Family Medicine
ACCELERATE: Evacetrapib’s clinical failure sinks lipid-drug class
MDedge Family Medicine

Related Articles

  • Applied Evidence

    Prolotherapy: Can it help your patient?

    Prolotherapy appears to be effective for Achilles tendinopathy and knee osteoarthritis, but has limited efficacy for low back pain. Find out when—...